Skip to main content

Chemomab Therapeutics Ltd.

corporate_fare Company Profile

Chemomab Therapeutics Ltd.

CMMB·NASDAQ·Life Sciences·CIK 0001534248

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on discovering and developing innovative therapeutics for fibrotic and inflammatory diseases with high unmet needs. The company has developed nebokitug, a monoclonal antibody designed to bind and block the activity of the soluble protein CCL24. Nebokitug targets CCL24, also known as eotaxin-2, a chemokine that promotes cellular processes regulating inflammatory and fibrotic activities through the CCR3 receptor. CCL24 is expressed in immune cells, endothelial cells, and epithelial cells. Nebokitug is a novel CCL24 inhibiting product candidate with dual anti-fibrotic and anti-inflammatory activity. This approach is being developed for difficult-to-treat rare diseases, or orphan indications, such as primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc), for which patients lack established disease-modifying or standard-of-care treatment options. The company estimates approximately 70,000 patients suffer from PSC in the United States, European Union, and Japan, representing a more than $1 billion market opportunity. Approximately 170,000 patients suffer from SSc in these same markets, representing a more than $1.5 billion market opportunity. Nebokitug, the lead clinical product candidate, is a first-in-class humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways. The company has completed a Phase 2 clinical study in PSC, a rare obstructive and cholestatic liver disease. Positive topline results from the double-blinded portion of this trial were reported in July 2024, and results from the open label part were reported in March 2025. The company had an End-of-Phase 2 meeting with the FDA in December 2024.

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for CMMB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for CMMB spans SCHEDULE 13D, DEFA14A, DEFM14A, 6-K.

Recent high-impact activity:

  • Scipher Discloses 10.4% Chemomab Stake After $1.1M Note-Funded ADS Purchase
  • Chemomab Supplement Discloses $1.1M Scipher ATM Purchase and Updated Merger Exchange Ratio
  • Chemomab Sets Dec 4 Vote on Scipher Merger; Holders Get 32% of Combined Company
  • Chemomab Halves Combined-Company Share Count to 5M in Merger Amendment No. 2
  • Chemomab Amends Merger Agreement to Set 10M-Share Post-Merger Structure

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$8.99M
Diluted EPS
$0.02
Op. Cash Flow
-$11.13M
Free Cash Flow
-$11.13M
Cash & Equivalents
$7.56M
Debt / Equity
0.00×
Shares Outstanding
510.23M sh
Source: 20-F · filed 2026-03-23 · accession 0001178913-26-001593

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 5,139 shares in CMMB as of the October 30, 2026 settlement, a 63.0% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 57.1% of CMMB volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)5,139 shares as of October 30, 2026
Change vs prior period▼ 63.0%
Days to cover1.00 at avg daily volume of 48,290
Daily short volume (FINRA facilities)57.1% of 35,230 shares on November 20, 2026
5-day average short volume26.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

CMMB files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with C →
$1.24 +8.77% today
52-week range · as of 2026-11-10 $0.9201 – $2.99
Market cap
$9.18M
Volume
70.8K (1.2× avg)
3-mo avg 60K
Live data · 2026-11-21 08:43 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CMMB - Latest Insights

CMMB
Nov 10, 2026, 5:30 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $1.35
Real-time Price: $1.24 info
Change: -$0.105 (-8%) info
Market Cap: $9.176M info
CMMB
Nov 10, 2026, 5:26 PM EST
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $1.35
Real-time Price: $1.24 info
Change: -$0.105 (-8%) info
Market Cap: $9.176M info
CMMB
Oct 30, 2026, 4:32 PM EDT
Filing Type: DEFM14A
Importance Score:
8
Price at Filing: $1.12
Real-time Price: $1.24 info
Change: +$0.120 (+11%) info
Market Cap: $9.176M info
CMMB
Oct 19, 2026, 5:28 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.19
Real-time Price: $1.24 info
Change: +$0.050 (+4%) info
Market Cap: $9.176M info
CMMB
Sep 30, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.19
Real-time Price: $1.24 info
Change: +$0.050 (+4%) info
Market Cap: $9.176M info
CMMB
Sep 25, 2026, 5:28 PM EDT
Filing Type: S-4
Importance Score:
9
Price at Filing: $2.17
Real-time Price: $1.24 info
Change: -$0.9298 (-43%) info
Market Cap: $9.176M info
CMMB
Sep 09, 2026, 4:00 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $2.65
Real-time Price: $1.24 info
Change: -$1.41 (-53%) info
Market Cap: $9.176M info
CMMB
Aug 19, 2026, 9:16 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.08
Real-time Price: $1.24 info
Change: -$0.8443 (-41%) info
Market Cap: $9.176M info
CMMB
Aug 19, 2026, 8:29 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $2.08
Real-time Price: $1.24 info
Change: -$0.8443 (-41%) info
Market Cap: $9.176M info
CMMB
Jul 16, 2026, 4:05 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $1.57
Real-time Price: $1.24 info
Change: -$0.330 (-21%) info
Market Cap: $9.176M info
CMMB
Jul 08, 2026, 7:36 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $3.05
Real-time Price: $1.24 info
Change: -$1.81 (-59%) info
Market Cap: $9.176M info
CMMB
Jul 08, 2026, 7:34 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $2.89
Real-time Price: $1.24 info
Change: -$1.65 (-57%) info
Market Cap: $9.176M info
CMMB
Jun 02, 2026, 4:03 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.74
Real-time Price: $1.24 info
Change: -$0.500 (-29%) info
Market Cap: $9.176M info
CMMB
May 14, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.74
Real-time Price: $1.24 info
Change: -$0.500 (-29%) info
Market Cap: $9.176M info
CMMB
Mar 23, 2026, 4:07 PM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $1.68
Real-time Price: $1.24 info
Change: -$0.440 (-26%) info
Market Cap: $9.176M info
CMMB
Mar 20, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $1.78
Real-time Price: $1.24 info
Change: -$0.540 (-30%) info
Market Cap: $9.176M info
CMMB
Mar 19, 2026, 8:05 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.00
Real-time Price: $1.24 info
Change: -$0.760 (-38%) info
Market Cap: $9.176M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets